The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B

Auris Nasus Larynx

Volumn 38, Issue 3, 2011, Pages 312-318

  Eser Karlidag, Gulden ^a   Karlidag, Turgut ^b   Demirdag, Kutbettin ^b   Keles, Erol ^b  

^a Elazig Education and Research Hospital   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis B; Hearing loss; Pegylated interferon

Indexed keywords

LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ADULT; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEARING; HEARING IMPAIRMENT; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OTALGIA; OUTCOME ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SOUND INTENSITY; TINNITUS; VERTIGO;

ADULT; ANTIVIRAL AGENTS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EARACHE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POSTURAL BALANCE; TINNITUS; VESTIBULAR FUNCTION TESTS; YOUNG ADULT;

EID: 79952737140     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2010.10.007     Document Type: Article

References (20)

1. World Health Organization. World Health Organization Hepatitis B Fact Sheet; 1998.
2. Vassiliadis T., Patsiaoura K., Tziomalos K., Gkiourtzis T., Giouleme O., Grammatikos N., et al. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006, 12:2417-2422.
3. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
4. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002. Hepatology 2002;36(Suppl. 1):S3-20.
5. Formann E., Stauber R., Denk D.M., Jessner W., Zollner G., Munda-Steindl P., et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004, 99:873-877.
6. Wong V.K., Cheong-Lee C., Ford J.A., Yoshida E.M. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. World J Gastroenterol 2005, 11:5392-5393.
7. Simdon J., Watters D., Bartlett S., Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis 2001, 32:1623-1627.
8. Brinkman K., Kakuda T.N. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. Curr Opin Infect Dis 2000, 13:5-11.
9. Hall J.W., Chandler D. Tympanometry in clinical audiology. Handbook of clinical audiology 1994, 283-289. Williams & Wilkins, Baltimore. J. Katz (Ed.).
10. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
11. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
12. Kaygusuz I., Ozturk Kaygusuz T., Ozturk A., Kilic S.S., Karlidag T., Keles E., et al. Effects of interferon-alpha2b on hearing. Int J Audiol 2004, 43:438-441.
13. Cadoni G., Marinelli L., De Santis A., Romito A., Manna R., Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol 1998, 112:962-963.
14. Piekarska A., Jozefowicz-Korczynska M., Wojcik K., Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol 2007, 46:345-350.
15. Johnson K., Sargent L.A., Galizio C., Ubogu E.E. Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. Eur J Gastroenterol Hepatol 2008, 20:1110-1114.
16. Kanda Y., Shigeno K., Matsuo H., Yano M., Yamada N., Kumagami H. Interferon-induced sudden hearing loss. Audiology 1995, 34:98-102.
17. Lorenz R.R., Solares C.A., Williams P., Sikora J., Pelfrey C.M., Hughes G.B., et al. Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. J Neuroimmunol 2002, 130:173-178.
18. Tunca A., Erbayrak M., Aytaç S., Türkay C. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol 2004, 15:97-99.
19. Kanda Y., Shigeno K., Kinoshita N., Nakao K., Yano M., Matsuo H. Sudden hearing loss associated with interferon. Lancet 1994, 343:1134-1135.
20. Elloumi H., Houissa F., Hadj N.B., Gargouri D., Romani M., Kharrat J., et al. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007, 13:5411-5412.